A first in disease phase 2, randomised, controlled trial of Granulocyte-Macrophage Colony-Stimulating factor neutralisation for Axial Spondyloarthritis (NAMASTE study)

Jones C., Al-Mossawi M., MacDonald J., Fisher B., Cook J., Teh J., Taylor P., Bowness P.

Type

Journal article

Journal

Lancet rheumatology

Publisher

Elsevier

Publication Date

25/04/2024

Keywords

namilumab, clinical trial, axial spondyloarthritis, biological, GM-CSF, anti-GM-CSF

Permalink